Candesartan + Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glucose Intolerance
Conditions
Glucose Intolerance, Obesity
Trial Timeline
Jun 1, 2006 → Feb 1, 2012
NCT ID
NCT00319202About Candesartan + Placebo
Candesartan + Placebo is a approved stage product being developed by AstraZeneca for Glucose Intolerance. The current trial status is terminated. This product is registered under clinical trial identifier NCT00319202. Target conditions include Glucose Intolerance, Obesity.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00699452 | Phase 3 | UNKNOWN |
| NCT00319202 | Approved | Terminated |
| NCT00328302 | Approved | UNKNOWN |
| NCT00634712 | Phase 3 | Completed |
| NCT00634309 | Phase 3 | Completed |
| NCT00634400 | Phase 3 | Completed |
Competing Products
17 competing products in Glucose Intolerance
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Alpha lipoic acid + Olmesartan + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Exenatide + Metformin | Eli Lilly | Approved | 85 |
| AZD1656 | AstraZeneca | Phase 1 | 33 |
| Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg | Merck | Phase 2 | 52 |
| Sitagliptin-Metformin + Metformin + Placebo pill | Merck | Approved | 85 |
| Comparator: exenatide + Comparator: exenatide + Comparator: Placebo | Merck | Phase 1 | 33 |
| Placebo + Januvia | Merck | Phase 2 | 52 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| Ramipril + Rosiglitazone | Pfizer | Phase 3 | 76 |
| HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| GFT505 80mg + Placebo | Genfit | Phase 2 | 44 |